title: S1. Rituximab for ANCA-associated vasculitis: the experience in the United States.
authors.affiliation: Mayo Clinic, Division of Pulmonary and Critical Care Medicine, Rochester, MN 55905, USA.
authors.forename: Jeremy M
authors.initials: JM
authors.lastname: Clain
authors.forename: Ulrich
authors.initials: U
authors.lastname: Specks
mesh_terms: D000368:Aged; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000175:diagnosis / Q000188:drug therapy*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015267:Churg-Strauss Syndrome / Q000188:drug therapy; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D017277:Drug Approval; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use; D014890:Granulomatosis with Polyangiitis / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D005938:Glucocorticoids; D000069283:Rituximab; D003520:Cyclophosphamide